Why the study?
Does canrenone added to optimal treatment improve cardiac remodeling in patients with mild chronic heart failure (NYHA class II)?
Does canrenone added to optimal treatment improve cardiac remodeling in patients with mild chronic heart failure (NYHA class II)?
In patients with mild heart failure, adding canrenone to optimal therapy improves ejection fraction and reduces BNP, though it does not significantly affect LVEDV.
Canrenone addition fails to reduce LVEDV in mild HF; challenges further MRA benefit on remodeling beyond current optimal therapy.
Canrenone on top of optimal treatment for HF did not have additional effects on LVEDV, but it increased EF, and reduced left atrial size and circulating BNP, with potential beneficial effects on outcome. A large-scale randomized study should be implemented to confirm benefits on cardiovascular outcomes in patients with HF in NYHA class II.
No takes yet. Share an insight, caveat, or question.
Boccanelli et al. (2009) studied this question.